Search Results - "Dooley, KE"

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis by Dheda, Keertan, Prof, Gumbo, Tawanda, Prof, Maartens, Gary, Prof, Dooley, Kelly E, PhD, McNerney, Ruth, PhD, Murray, Megan, Prof, Furin, Jennifer, PhD, Nardell, Edward A, Prof, London, Leslie, Prof, Lessem, Erica, MPH, Theron, Grant, PhD, van Helden, Paul, Prof, Niemann, Stefan, Prof, Merker, Matthias, Dr rer nat, Dowdy, David, PhD, Van Rie, Annelies, Prof, Siu, Gilman K H, PhD, Pasipanodya, Jotam G, PhD, Rodrigues, Camilla, MD, Clark, Taane G, Prof, Sirgel, Frik A, PhD, Esmail, Aliasgar, MBBS, Lin, Hsien-Ho, ScD, Atre, Sachin R, PhD, Schaaf, H Simon, Prof, Chang, Kwok Chiu, MBBS, Lange, Christoph, Prof, Nahid, Payam, Prof, Udwadia, Zarir F, MD, Horsburgh, C Robert, Prof, Churchyard, Gavin J, PhD, Menzies, Dick, Prof, Hesseling, Anneke C, Prof, Nuermberger, Eric, Prof, McIlleron, Helen, Prof, Fennelly, Kevin P, MD, Goemaere, Eric, PhD, Jaramillo, Ernesto, PhD, Low, Marcus, MA, Jara, Carolina Morán, RN, Padayatchi, Nesri, PhD, Warren, Robin M, Prof

“…Summary Global tuberculosis incidence has declined marginally over the past decade, and tuberculosis remains out of control in several parts of the world…”
Get full text

Importance of Drug Pharmacokinetics at the Site of Action by Rizk, ML, Zou, L, Savic, RM, Dooley, KE

“…CSF as well as variability in penetration of drugs to the brain and CSF related to inflammation and breakdown of vascular integrity, the dynamics of drug…”
Get full text

Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure–response relations from two phase II clinical trials by Savic, RM, Weiner, M, MacKenzie, WR, Engle, M, Whitworth, WC, Johnson, JL, Nsubuga, P, Nahid, P, Nguyen, NV, Peloquin, CA, Dooley, KE, Dorman, SE

“…Rifapentine is a highly active antituberculosis antibiotic with treatment‐shortening potential; however, exposure–response relations and the dose needed for…”
Get full text

Impact of Diabetes Mellitus on Treatment Outcomes of Patients with Active Tuberculosis by Dooley, Kelly E, Tang, Tania, Golub, Jonathan E, Dorman, Susan E, Cronin, Wendy

“…Diabetes mellitus (DM) is an emerging chronic health condition of developed and developing countries. We conducted a retrospective cohort study of patients…”
Get full text

Clinical standards for drug-susceptible pulmonary TB by Akkerman, O. W., Duarte, R., Tiberi, S., Schaaf, H. S., Lange, C., Alffenaar, J. W. C., Denholm, J., Carvalho, A. C. C., Bolhuis, M. S., Borisov, S., Bruchfeld, J., Cabibbe, A. M., Caminero, J. A., Carvalho, I., Chakaya, J., Centis, R., Dalcomo, M. P., D´Ambrosio, L., Dedicoat, M., Dheda, K., Dooley, K. E., Furin, J., García-García, J-M., van Hest, N. A. H., de Jong, B. C., Kurhasani, X., Märtson, A. G., Mpagama, S., Torrico, M. Munoz, Nunes, E., Ong, C. W. M., Palmero, D. J., Ruslami, R., Saktiawati, A. M. I., Semuto, C., Silva, D. R., Singla, R., Solovic, I., Srivastava, S., de Steenwinkel, J. E. M., Story, A., Sturkenboom, M. G. G., Tadolini, M., Udwadia, Z. F., Verhage, A. R., Zellweger, J. P., Migliori, G. B.

“…BACKGROUND: The aim of these clinical standards is to provide guidance on 'best practice´ for diagnosis, treatment and management of drug-susceptible pulmonary…”
Get full text

Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children by Savic, RM, Ruslami, R, Hibma, JE, Hesseling, A, Ramachandran, G, Ganiem, AR, Swaminathan, S, McIlleron, H, Gupta, A, Thakur, K, van Crevel, R, Aarnoutse, R, Dooley, KE

“…Pediatric tuberculous meningitis (TBM) is a highly morbid, often fatal disease. Standard treatment includes isoniazid, rifampin, pyrazinamide, and ethambutol…”
Get full text

Standards for clinical trials for treating TB by du Cros, P., Greig, J., Alffenaar, J.-W. C., Cross, G. B., Cousins, C., Berry, C., Khan, U., Phillips, P. P. J., Velásquez, G. E., Furin, J., Spigelman, M., Denholm, J. T., Thi, S. S., Tiberi, S., Huang, G. K. L., Marks, G. B., Turkova, A., Guglielmetti, L., Chew, K. L., Nguyen, H. T., Ong, C. W. M., Brigden, G., Singh, K. P., Motta, I., Lange, C., Seddon, J. A., Nyang'wa, B-T., Maug, A. K. J., Gler, M. T., Dooley, K. E., Quelapio, M., Tsogt, B., Menzies, D., Cox, V., Upton, C. M., Skrahina, A., McKenna, L., Horsburgh, C. R., Dheda, K., Marais, B. J.

“…BACKGROUND: The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best…”
Get full text

Safety and Pharmacokinetics of Escalating Daily Doses of the Antituberculosis Drug Rifapentine in Healthy Volunteers by Dooley, K E, Bliven-Sizemore, E E, Weiner, M, Lu, Y, Nuermberger, E L, Hubbard, W C, Fuchs, E J, Melia, M T, Burman, W J, Dorman, S E

“…Rifapentine (RPT) is an antituberculosis drug that may shorten treatment duration when substituted for rifampin (RIF). The maximal tolerated daily dose of RPT…”
Get full text

New Paradigm for Translational Modeling to Predict Long‐term Tuberculosis Treatment Response by Bartelink, IH, Zhang, N, Keizer, RJ, Strydom, N, Converse, PJ, Dooley, KE, Nuermberger, EL, Savic, RM

“…Disappointing results of recent tuberculosis chemotherapy trials suggest that knowledge gained from preclinical investigations was not utilized to maximal…”
Get full text

Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities by McAnaw, S.E, Hesseling, A.C, Seddon, J.A, Dooley, K.E, Garcia-Prats, A.J, Kim, S, Jenkins, H.E, Schaaf, H.S, Sterling, T.R, Horsburgh, C.R

“…Highlights • Current barriers to pediatric multidrug-resistant tuberculosis clinical trials are discussed. • Recommendations for a science-based framework to…”
Get full text

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults by Furin, J., Alirol, E., Allen, E., Fielding, K., Merle, C., Abubakar, I., Andersen, J., Davies, G., Dheda, K., Diacon, A., Dooley, K. E., Dravnice, G., Eisenach, K., Everitt, D., Ferstenberg, D., Goolam-Mahomed, A., Grobusch, M. P., Gupta, R., Harausz, E., Harrington, M., Horsburgh, C. R., Lienhardt, C., McNeeley, D., Mitnick, C. D., Nachman, S., Nahid, P., Nunn, A. J., Phillips, P., Rodriguez, C., Shah, S., Wells, C., Thomas-Nyang'wa, B., du Cros, P.

“…Drug-resistant tuberculosis (DR-TB) is a growing public health problem, and for the first time in decades, new drugs for the treatment of this disease have…”
Get full text

Isoniazid hair concentrations in children with tuberculosis: a proof of concept study by Mave, V., Chandanwale, A., Kinikar, A., Khadse, S., Kagal, A., Gupte, N., Suryavanshi, N., Nimkar, S., Koli, H., Khwaja, S., Bharadwaj, R., Joshi, S., Horng, H., Benet, L. Z., Ramachandran, G., Dooley, K. E., Gupta, A., Gandhi, M.

“…Assessing treatment adherence and quantifying exposure to anti-tuberculosis drugs among children is challenging. We undertook a 'proof of concept' study to…”
Get full text

Qualitative study of perceived causes of tuberculosis treatment default among health care workers in Morocco by Kizub, D., Ghali, I., Sabouni, R., Bourkadi, J. E., Bennani, K., El Aouad, R., Dooley, K. E.

“…SETTING: In Morocco, tuberculosis (TB) treatment default is increasing in some urban areas.OBJECTIVE: To provide a detailed description of factors that…”
Get full text

Empiric Treatment of Community-Acquired Pneumonia with Fluoroquinolones, and Delays in the Treatment of Tuberculosis by Dooley, Kelly E., Golub, Jonathan, Goes, Fernando S., Merz, William G., Timothy, Sterling R.

“…Fluoroquinolones, which are widely used to treat community-acquired pneumonia, also have excellent in vitro activity against Mycobacterium tuberculosis. A…”
Get full text

Fluoroquinolone Resistance in Patients with Newly Diagnosed Tuberculosis by Ginsburg, Amy Sarah, Hooper, Nancy, Parrish, Nikki, Dooley, Kelly E., Dorman, Susan E., Booth, Jay, Diener-West, Marie, Merz, William G., Bishai, William R., Sterling, Timothy R.

“…Fluoroquinolones are widely used for the treatment of bacterial infections and are also second-line therapy for tuberculosis. However, fluoroquinolone…”
Get full text

Herbal Remedies in Resource-poor Settings: Friend or Foe? by Dooley, KE, Flexner, C, Andrade, AS

Get full text

Treatment of latent tuberculosis infection: challenges and prospects by Dooley, Kelly E, Sterling, Timothy R

“…This article reviews the treatment of latent tuberculosis infection in HIV-seropositive and HIV-seronegative persons…”
Get more information

A 39-year-old man with hip pain and respiratory failure by Dooley, Kelly E, Sinha, Saurabh R, Haponik, Edward, Conwit, Robin, Sevransky, Jonathan E

Get more information